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TheC133-associated TCRa/(3heterodimeris expressedonthe surface ofthe vast
majority of mature CD4+ or CD8+ Tcells in the peripheral blood (PB)1 and lym-
phoid organs (1-3). A second class ofTCRs consistingofy andSchains (TCRy/S),
also CD3-associated, is found mainly in the double-negative (CD4-8-) Tcell popu-
lation (4-6). The TCR and CD3 are thought to form a functional unit in antigen
recognition and signal transduction, and the association ofall the components ap-
pears to be essential for cell surface expression of the molecular complex (for a re-
view, see reference7). Thus, inactivation ofagene encoding a protein ofthe TCR/CD3
complex should lead to loss of surface TCR/CD3 expression and thereby result in
defectiveantigenrecognition and cell activation. Manymutant cell lineslacking surface
expression oftheTCR/CD3 complexhave been obtained from human Tlymphoma
cellsexposed to radiation orchemical mutagens (8-17). These cells failed to respond
to various mitogen and antibody stimuli(9, 12-15). Most ofthese mutant lines were
found to have defects in TCR expression (mostly TCR-a) rather than CD3 expres-
sion and intracellular accumulation ofthe incompletely assembledcomplexes. This
suggests that TCR genes are more susceptible to mutagenesis than CD3 genes.
These fourTCR genes are all located on chromosomes 7 (a, y) and 14 (a, S) (18).
Similar to Ig genes in B cells, but unlike ordinary autosomal genes, only one oftwo
TCR alleles in T cells is thought to be active in protein expression (19). Although
the mechanism ofallelic exclusion in TCR expression is not fully understood at the
molecularlevel, such a mechanism may be essential inorder fora given T cell clone
to have only one idiotype on its TCR, which is necessary for the maintenance of
anorderedimmune network. Asaresult ofallelicexclusion, it is expected thatTCR
expression-loss variants are frequently generated byasingle inactivationevent even
though TCR genes are autosomally located. Infact, many mutant cell lines lacking
the TCR have been established in vitro from T lymphoma cell lines (8-17), as men-
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tioned above, although the mutation rates have not been determined yet. In this
report, we will address the question of whether such variant cells with alterations
of TCR/CD3 expression exist in detectable numbers among in vivo mature T cell
populations. Aberrant, immature T cellswith nonproductive rearrangements of both
TCR alleles are assumed to die in the thymus (19, 20). It is unknown whether a
similar selection mechanism depletes such aberrant mature T cells induced in pe-
riphery by somatic mutations. If such variant T cells do exist, by what molecular
alterations and at what frequencies have they been generated?
For this study, we detected and isolated variants with loss or alteration of TCR/CD3
expression from a human PB CD4' T cell population using a cell sorter. Most of
these variants had abnormalities in the expression of either the TCRa or -(3 chain.
The TCR abnormalities probably were caused by inactivation or alteration of the
TCR genes, which resulted in defect or decrease in membrane transport of the in-
complete TCR/CD3 complex. The variant frequency was measured for normal donors
and patients with genetic diseases showing somatic gene instability. Implications for
the T cell immunodeficiency and malignancy will also be discussed.
Materials and Methods
mAbs.
￿
mAbs used were anti-Leu-4 (CD3), NUT3 (CD3) (21), anti-Leu-3a (CD4), anti-
Leu-6 (CD1), anti-Leu-5b (CD2), anti-Leu-1 (CD5), anti-Leu-2a (CD8), anti-Leu-7 (CD57),
anti-Leu-11a (CD16), anti-Leu-16 (CD20), anti-Leu-M3 (CD14), anti-IL-2-R (CD25), WT31
(TCRag) (22), /3F1 (TCR(3) (23), aF1 (TCRa), antiTCRbl (TCR6) (24), and antiTCR-
y/b1 (TCR-y or -y/b complex) (25). Anti-Leu and WT31 (TCR-I) mAbs were purchased
from Becton Dickinson Immunocytometry Systems (San Jose, CA). NUT3 mAb was ob-
tained from Seikagaku Kogyo Co. (Tokyo, Japan). AntiTCRbl mAb was purchased from
T Cell Science, Inc. (Cambridge, MA), and antiTCR-y/bl mAb was kindly provided by Dr.
J . Borst, The Netherlands Cancer Institute (Amsterdam, The Netherlands). Preparation and
characterization of aFl antibody is described in a technical data sheet provided by T Cell
Science, Inc.
Sorting and Culture of Variant T Cells.
￿
PB samples were derived from healthy volunteers
and from children with genetic diseases such as ataxia telangiectasia (AT), Fanconi's anemia
(FA), and Down's syndrome (DS) . PBMC were isolated from blood by density separation
using Ficoll/Hypaque. PBMCs were stained with fluorescein-labeled anti-Leu-3a (FL-anti-
Leu-3a) and phycoerythrin-labeled anti-Leu-4 (PE-anti-Leu-4) antibodies, as described by
the supplier. Before flow cytometry, propidium iodide (PI) was added at a final concentration
of 10 ug/ml to gate out dead cells. For sorting variant CD4' T cells with loss or decreased
expression ofCD3, a sorting window was set to the region where the surface CD3 level was
<4°Jo of that of normal CD4' cells. Approximately 1,000 cells were sorted and cultured with
GIT medium (Wako Pure Chemical Industry, Osaka, Japan) containing 10% FCS (M. A.
Bioproducts, Walkersville, MD), PHA (1 :1600, Difco Laboratories, Detroit, MI), rIL-2 (2
ng/ml; Takeda Chemical Industries, Osaka, Japan), and feeder cells for 2 wk. A mixture
of allogeneic PBMCs from three normal donors and from an allogeneic B cell line, OKIB,
established by us was used as feeder cells after irradiation with 50 Gy. For cloning variant
T cells, immediately after sorting, cells were distributed into 96-well plastic plates at a mean
frequency of N1 cell per well, and were cultured for 4 wk under the same condition described
above. Normal CD4' clones were also established from normal donors and AT patients.
Clones derived from these cultures were expanded with feeder cells for further analysis.
Cytoplasmic Immunofluorescence.
￿
Variant and normal T cell clones were cytocentrifuged onto
a glass slide and fixed with acetone for 10 min at -20°C. The fixed cell specimens were in-
cubated with the first antibodies (anti-Leu-4, WT31, aFl, OF1, TCRbl, and TCR-,y/61) or
control myeloma proteins (MOPC21 and UPC10) for 1 h at room temperature. After being
washed with PBS three times, the specimens were stained with F(aV)z fragments of anti-KYOIZUMI ET AL.
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mouse Igs (Tago Inc., Burlingame, CA) for 45 min. After extensive washing, the samples
were fixed with 117o paraformalin for observation under a fluorescence microscope (Nikon,
Tokyo, Japan).
Immunoprecipitation Analysis.
￿
Radiolabeling and immunoprecipitation were performed using
the following methods: T cell clones were biosynthetically labeled with 37 MBq 35S-methio-
nine (35S-Met) (New England Nuclear, Boston, MA) in RPMI 1640 Met-free medium at
37°C for 6 h. For
1251 surface labeling, cells were incubated with 74 MBq Na
1251 (New En-
gland Nuclear) at 30°C for 4 min in 150 Al PBS containing 100 wg lactoperoxidase (Sigma
Chemical Co., St. Louis, MO) and 20 Al of 0.03% H202, and the mixture was further incu-
bated at 25°C for 10 min (26). After radiolabeling, cells were washed with PBS five times
and lysed in the extraction buffer (10 mM triethanolamine, 0.15 M NaCl, pH 7.8 [containing
as inhibitors], 10 mM iodacetamide, 1 mM EDTA, 1 mM PMSF, and 1 p.g/ml each ofleupeptin,
antipain, pepstatin, and chymostatin) containing I% digitonin or 0.5% NP-40, as described
in a previous report (27) . Immunoprecipitationswere performed by incubating the detergent
extracts with 2 Rg ofantibody on ice for 3-4 h, then adding a 20 1A-packed volume ofprotein
A-Sepharose (Pharmacia LKB Biotechnology AB, Uppsala, Sweden), and further incubating
the mixture for 1 h. For antiTCR61 and MOPC 21 antibodies, protein A-Sepharose was
precoated with rabbit anti-mouse Igs. Immunoprecipitates were washed five times in the same
buffer used for cell extraction and were solubilized in reducing or nonreducing Laemmli sample
buffer subjected to SDS-PAGE.
Southern Blotting
￿
High-molecular weight genomic DNA was extracted from variant T
cell clones and a B cell line, as described in a previous report (28). DNA samples (10 ug)
were digested with Barn HI, subjected to electrophoresis through 0.7% agarose, transferred
to nitrocellulose filters, and probed with cDNA ofthe TCR/3 C region gene (29). 12P labeling
was performed using a random primer method (Amersham International, Amersham, UK).
Filters were washed with 0.1 x SSC and 0.1% SDS at 65°C.
Chromosome Analysis.
￿
Variant T cell clones were examined for karyotype analysis using
the G-banding method (30). Briefly, after exposure of T cells to colcemid (0.05 hg/ml) for
4 h, chromosome specimens were prepared by an air-dried method. The slides were treated
with a 0.1% trypsin solution (Gibco Laboratories, Grand Island, NY) for 15-20 s at 30°C
and then stained with 2% Giemsa solution for 15 min. In each clone, >10 metaphases were
analyzed.
Results
Detection of Variant T Cells.
￿
Flow cytometry is useful for detecting and isolating
cells with rare phenotypes in vitro (31) and in vivo (32-34) at frequencies of >10-6.
To detect variant CD4+ T cells with altered TCR/CD3 expression, two-color fluo-
rescence analysis ofnormal PBL stained with FL-anti-CD4 and PE-anti-CD3 anti-
bodies was performed using a cell sorter. Using WT31 antibody to react with the
TCRa/(3 complex did not work for detecting variants; the resolution between posi-
tive and negative cells was not great enough. The sorting window was set in the
region for variant CD4+ cells, as shown in Fig. 1 A . Variant cells showed a discrete
cluster in the window and were observed in normal donors at a frequency of several
cells per 10,000 CD4 cells (Fig. 1 A). All events occurring in the variant window
were sorted onto a glass slide and were observed under a fluorescence microscope
to determine whether they exhibited an FL green fluorescence and not PE orange
fluorescence. Sorted cells were also stained with PI to examine the shapes of their
nuclei. Such experiments revealed that >95% of events appearing in the variant
window were apparently mononuclear cells with only FL fluorescence, not polymor-
phonuclearcells or debris. Other surface markers expressed in the variant cellswere
examined by two-color analysis using FL-labeled or PE-labeled anti-CD4 and anti-
CD3 with or without a third fluorescence-labeled antibody. Calculation of the differ-1984
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FIGURE 1.
￿
Detection and isolation of variant CD4' T cells with defective or decreased CD3
expression. (A) Flow distribution of 106 PBL stained with FL-anti-CD4 (Leu-3a) and PE-anti-
CD3 (Leu-4) antibodies. Before flow cytometry, propidium iodide was added to gate out dead
cells(DC). Fortwo-color analysis, thelymphocyte fraction wasgatedby forward and right angle
light scatter. Contours differ by afactor of 10 in events per channel, with the lowest contour rep-
resentingone event per channel. To sort variant Tcells, a sortingwindow was set in theregion
shown in this figure. Approximately 103 cellswere sorted and cultured with PHA, r-IL-2, and
feeder cells for 2 wk. Cultured T cells were analyzed for their CD3 and CD4 expression with
FL-Leu-3aandPE-Leu-4 antibodies (B), TCRa/0expression with FL-WT31 antibody (C), and
CD2 expression by indirect immunofluorescence with anti-Leu-5b (D). Broken linesrepresent
control staining with myeloma IgG antibody.
encebetweenthe frequencies ofcells in the window with and without the third anti-
body staining showed that >90% ofthe variants expressed pan-T cellmarkers (CD2
and CD5), butnotTCRa//3, monocyte marker (CD14), orpan-B cellmarker (CD20).
These results strongly suggested that most events in the variant window are mature
CD4+ T cells with altered TCRa//3 CD3 expression.
To confirm the presence of CD4+ T cells with altered TCR/CD3 expression,
-1,000 cells were sorted from the window and expanded by bulk culture for 2 wk
withfeeder cells, PHA, and rIL-2. Mostofthecells grown inthisculture were found
to lack or have decreased surface expression of the TCRa/0 -CD3 complex with
minor contamination by normal CD4+ cells (Fig. 1, B and C). These cultured cellsKYOIZUMI ET AL.
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expressed CD2 antigens (Fig. 1 D) and IL-2-Rs (data not shown), suggesting that
PHAmay activate some populations ofTCR/CD3 - T cells via CD2 molecules to
induce the expression of theIL-2-R, as discussed below . Other surface marker char-
acteristics of these cells were CD1-, 5 + , 8- , 11 - , 16 - , 20- , and 57', indicating that
these variant cells have the surface phenotype of typically mature CD4' T cells, ex-
cept for altered TCR/CD3 expression . Previous studies using a TCRdefective T
lymphoma cell line have demonstrated the accumulation of CD3 molecules in cy-
toplasm (7-17) . Similarcytoplasmic expression ofCD3 wasobserved in these in vivo
derived variant T cells by immunofluorescence staining of fixed cells (Fig . 2) .
Isolation andCharacterization of Variant Clones.
￿
Next, we establishedcloned variant
CD4' T cell lines from PB forfurther molecular analysis ofTCR/CD3 expression .
Although the cloning efficiency for variant cells was N5-10% (much lower than the
50-80% for normal CD4' T cells), 37 variantT cell clones couldbe established from
four normal healthy donors by limiting dilution ofsorted cells . Thesevariant clones
were classified into three types, according to the surface staining characteristics with
anti-CD3 (Leu-4) and anti-MRWo (WT31) antibodies (Fig . 3, Table I) . Type I
clones lackedmembrane expression ofbothCD3 andTCRca//3. Type II showed low
expression ofCD3, but the reactivity withWT31 antibody was faint or almost nega-
tive . Type III demonstrated a low level of expression of both CD3 and MR-a//3 .
These variant phenotypes have been stable in culture for >6 mo.
Expression of CD3, TCRa, and TCR/3 of the variant clones was analyzed by
cytoplasmic immunofluorescence andimmunoprecipitation usingvarious antibodies
against CD3 (Leu-4 orNUT3 antibody), TCRa/(3 dimer (WT31), TCRa (aiFl),
TCR0(fl),TCR6 (antiTCRS1), andTCRy/S complex(anti-MR-y/61) . As shown
in Table I, strong expression of CD3 in the cytoplasm was observed for all of the
variant clones . On the otherhand, the expression ofTCRa and -/3chains wasvari-
able . All of the type I clones were found to lack cytoplasmic expression of either
TCR-a or -0 chains as detected by uF1 or (OF1 antibodies, respectively. SDS-PAGE
analysis of 35S-Met-labeled polypeptides immunoprecipitated with anti-CD3 anti-
Fiouxa, 2 .
￿
Cytoplasmic expres-
sion ofCD3 antigens in CD4'
variant T cells by indirect im-
munofluorescence staining.1986
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FIGURE 3.
￿
Surface expression of the TCR/CD3 complex in variant T cell clones. Variant T
cell clones were stained with either PE-anti-CD3 (Leu-4) and FL-anti-CD4 (Leu-3a) (top) or FL-
WT31 antibodies (bottom). Broken lines represent control staining using FL-labeled myeloma
IgG protein.
body (NUT3) under nonreduced conditions also demonstrated that these clones
expressed only monomeric (40 kD), not dimeric, TCRs (Fig. 4A). No abnormali-
ties in theexpression ofCD3-6and-e were detected forthesevariantsbySDS-PAGE,
although otherCD3 subunits could not be labeled with 35S-Met in this labeling con-
dition (35). TheseTCRa or-(3chain monomers couldbe associated with CD3 mol-
TABLE I
Surface and Cytoplasmic Expression of the TCR/CD3 Complex in
Variant CD4+ T Cell Clones
Surface
￿
Cytoplasm
Antigens:
￿
CD3
￿
TCR-a/#
￿
CD3
￿
TCR-a/ft TCR-a TCR-# No. of
Antibodies: (Leu-4) (WT31) (Leu-4) (WT31) (ciFl) (,BFI) clones
++ - - + 6
Lt
￿
-
￿
+ +
￿
-
￿
+
￿
+
￿
3S
++ - - - 111
L L ++ + + + 5
37
Surface and cytoplasmic immunofluorescence was performed as described in Materials and
Methods.
' The cytoplasmic staining was scored as follows: - , negative; +, positive; + + , strong.
1 Low expression (see Fig. 3).
S Partial deletions of either TCR-a or -fl chain were detected by immunoprecipitation analy-
sis using anti-CD3 antibody (see Fig. 4).
II This variant clone was found to be reactive with TCR-61 antibody, but not with anti-TCR-
-y/dl antibody.KYOIZUMI ET AL .
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ecules, butthe molecular complexwas not successfully transportedto themembrane.
Thus, lack ofsurfaceTCR/CD3 complexexpressionin typeIclones can beexplained
simply by a defect of either TCRa or -(3 chain expression, as previously reported
in variant Tcelllines (7-15). Preliminary experiments using Northern blotting analysis
ofseveral type I variants also confirmed the defect of full-length mRNA synthesis
from either the MR-a or -0 gene.
Type II variants, which expressed CD3 on their cell surfaces at low levels, were
rather complicated, having variousTCR abnormalities. In type 11 variants, significant
reactivity with WT31 antibody could not be detected either on the cell surface or
in the cytoplasm (Fig. 3, Table I). But protein bands corresponding to TCR chains
were detected by SDS-PAGE analysis ofimmunoprecipitates of 1251-labeled surface
proteinwith anti-CD3 antibody(datanotshown). However, since TCR proteinbands
in SDS-PAGE were very weak for three offour type II clones listed in Table 1, these
three clones were labeled internally with "S-Met for further immunoprecipitation
experiments (Fig. 4 B). Those clones, which were reactive with both aFl and f3F1
antibodies, showed twoTCRprotein bandsunderreduced conditions; onewas normal
in size, but the other TCR chain had a relatively low molecular mass (indicated
by the arrowheads in Fig. 4 B). These TCR chains could form TCR heterodimers,
with lower molecular mass(60-65 kD) than normal TCRdimers (80kD), as shown
by nonreduced SDS-PAGE analysis. Using Northern blot analysis, it was demon-
strated that these variants expressed either full-length TCR-a or -a mRNA and a
relatively shortlength ofTCR/3or -a mRNA, respectively, suggesting that the small
size ofthe TCR chains observed by SDS-PAGE was due to partially deleted forms
of the TCR-a or -/3 proteins. It is possible that some part of the TCR framework
recognized byWT31 antibody is truncated in this type ofclone, so that the associa-
tion with CD3 required for surface expression ofthe complex cannot occur normally.
Another type II clone (Table I), which was not reactive with either a&I or OF1
antibodies, was found to express antiTCR-61-reactive antigens on its cell surface.
However, this clone was found nonreactive both on the cellsurfaceand inthecytoplasm
with antiTCR,y/61 antibody recognizingthe TCRy orTCRy/6complex(25). SDS-
PAGE patterns of 1251-labeled immunoprecipitates with either anti-CD3 or anti-
TCR61 antibodies revealed a TCR band (40 kD) under reduced conditions and
a disulphide-linked dimer (80 kD) detected under nonreduced conditions (Fig. 4
C). Northern blottinganalysisshowed the production offull-length mRNA forTCRy
in this clone, suggesting that this variant synthesized both TCRy and -6 chains;
therefore, the 40-kD band under reduced conditions was most likely an overlap of
the TCR-y and -S chains as described by Hochstenbach et al. (36). All these data
suggested that this CD4+ variant expressed disulphide-linked TCRy/S heterodimer
and that its TCR-y or -6 chain (most likely y chain) had a partial deletion ormuta-
tion in a region that may be recognized by antiTCR-y/S1 antibody.
Type III variants were found toexpressboth TCRy and-achains in thecytoplasm
byusingimmunofluorescence, but surface expression ofthe TCR/CD3 complex was
much lower than that ofnormal clones (Table I, Fig. 3). TCR expression of these
type III clones was also examined by immunoprecipitation of"S-Met-labeled pro-
teins with anti-CD3 antibodies. Although these clones appeared to produce both
TCR-a and -/3 chains at normal levels, the protein band correspondingto the TCR
dimer was very weak by SDS-PAGE analysis under nonreduced conditions (dataKYOIZUMI ET AL .
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not shown) . We speculate that these variants have some mutations in the framework
of either the TCR-a or -# protein, which did not alter the epitope structure recog-
nized by c&l, flFl, or WT31 antibodies . It is likely that such abnormalities in the
TCR chains consequently inhibit either the formation of theTCR dimer or its as-
sociation with CD3 molecules, so that surface expression of TCR/CD3 complex is
considerably diminished .
Rearrangement of71 CR Genes in Variant Clones.
￿
To examine the possibility that the
defect ofTCRa or -,Q chain expression of type I variants is due to the lack ofTCR
gene rearrangement, we analyzed theTCR genes of the variant clones by Southern
blot . Fig. 5 revealsthe restriction patterns of theTCRa genes from MR-0-defective
type I variants, demonstrating that TCR(3 genes were rearranged in all these vari-
ants . No evidence for loss ofthe entireTCR(3 constant (C/3)gene couldbe observed
by Southern analysis using the CO cDNA probe.
Among the 37 variant clones examined here, 11 clones derived from one of the
donors showed identical TCR-O gene rearrangement patterns (Fig. 5 shows four of
these clones), usingthree different restriction enzymes (Eco RI, Hind III, and Barn
HI). TheTCR-y gene forthese variants also revealed identicalrearrangements (data
not shown) . This reflects in vivo clonality, since T cell cloning had been done im-
mediately after cell sorting without preculture . TheTCR0 gene restriction patterns
by Barn HI digestion of these clones exhibited three rearranged bands (Fig . 5) . This
suggested the occurrence of gross alterations of theTCR# gene induced by partial
gene duplication or unequal sister chromatidexchange (19). It can be presumed that
such inactivation occurred in aTCRa gene ofaproliferatingT cell and thevariant
was clonally expanded in vivo .
Chromosome Aberration in Variants.
￿
It has long been observed that translocations
between chromosomes 7 and 14 are frequent in T cells from normal donors (37).
The breakpointson these chromosomes are also highly nonrandom, involving three
regions, i.e., 7(p13-15), 7(832-35), and 14(gll-12), whereTCRy,TCRa, andTCR
a/S genes, respectively, are located, according to recent studies (18) . The frequency
of t(7:14) has been reported to be 4 x 10-4 (37), which is very similar to the fre-
quency of TCR variants as described below. It is possible that t(7 :14) is accompa-
nied by inactivation ofTCR genes . If so, theTCR variants cloned here might fre-
quently bear aberrations of chromosomes 7 and 14 .
FIGURE 5 .
￿
Southernblot anal-
ysis ofTCRO gene rearrange-
ments in type I variant clones
(lanes 2-10) with defective
TCRft expression. EB virus-
transformed B cells from a
normal donor served as a con-
trol for the germ-line configu-
ration (lane 1) . For one clone
(lane 3), rearrangement was not
apparent with Barn HI diges-
tion, but dearrearranged bands
were detected in Eco RI restric-
tion pattern . Four variant
clones, as indicated by asterisks,
represent identically rearranged
bands .1990
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When we analyzed the chromosomes of 14 type I and five type II variant clones,
no t(7 :14) were observed. One type I clone showed a translocation between 14(gll)
and (13 q32) (Fig . 6) . Since this variant was found to be defective in TCRa expres-
sion but not inTCR(3 expression, it is very possible that this chromosome translo-
cation might have induced nonexpression in an active TCRcx gene allele that was
located at the breakpoint . TCR gene inactivation, however, accompanied chromo-
some translocations less frequently than we had expected . It may be possible that
variants bearing such chromosome aberrations cannot be cloned in culture due to
their inability to grow. Intrachromosomal rearrangements, i.e., duplications, dele-
tions, or insertions, also may be involved .
Variant Frequency In Vivo and In Vitro.
￿
As shown above, partial characterization
of TCR/CD3 variants in PB exhibited a variety ofTCR abnormalities . Next, we
measured the frequency of variant cells in either PB or culture by flow cytometry
in normal donors and in patients with hereditary disease showing instability of so-
matic genes.
The variant frequency was found to be almost constant in each donor, when five
normal donors were examined three or more times during 1 yr (coefficients ofvaria-
tion for each donor were <20%). Themean frequency for 127 normal donors was
-2.5 x 10-4 on average, and it significantly (p < 0.0001) increased with age (Fig .
7) . Since these variants should have a defect in antigen recognition and activation
for specific immune responses, theirincreasing frequency may be one of the factors
related to age-dependentdecrease inT cell function (fora review, see reference 38) .
FA patients showed higher variant frequencies than those ofnormal youngdonors,
but aDS patient had a normal frequency (Fig . 7) . Much higher variant frequencies
were observed in patients with AT. On the other hand, the heterozygous parents
of theAT patient no . 2 (in Fig . 7), were found to have frequencies of 3.4 and 3.5 x
10-4 , which are within the normal range. Thus, measurement of the TCR/CD3
variants in PB can be applied to the diagnosis of AT. AT is a recessive inherited
disease characterized by defectiveDNA repair after ionizing radiation (39, 40), and
it is known to have a high frequency of spontaneous somatic mutations of erythro-
cytes (41) and of lymphocyte chromosome aberrations (38), especially in chromo-
somes 7 and 14 (42, 43) . High radiation sensitivity ofT cells from these two AT
patients has been confirmed.We also found an elevationof in vivo frequencyof dele-
FIGURE 6 .
￿
Translocation between chromosomes
13 and 14 seen in the type I variant clone lacking
TCRa expression . 18 metaphases were examined
and all of them exhibited a reciprocal transloca-
tion t(13;14)(g32;qll) . Arrows indicate the break
points.17.9E
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FIGURE 7.
￿
Relationship betweendonor age andvariant
Tcell frequency in PB from 127 normal donors and five
patients with genetic diseases such as AT, FA, and DS.
Variant T cells are detected as shown in Fig. 1 A. Variant
frequency equals the value of the number of variants
occurring in the window divided by the total number
of CD4' cells. The line corresponds to a linear regres-
sion calculated from the variant frequencies for the nor-
mal donors.
tion type mutants at the glycophorin A locus of erythrocytes for AT patient no. 1
(unpublished observation).
It is also known that AT patients have a defect in thymus development (44) and
various dysfunctions in T cell response (39, 45-48). Such abnormal thymus devel-
opment might result in the defective maturation ofT cells and provide a source of
variant T cells with defective TCR/CD3 expression to the PB. However, as shown
in Fig. 8, normal T cell clones (CD3+4`) derived from AT patients revealed high
frequencies (1.5-5.0 x 10-3) of spontaneous loss of surface TCR/CD3 expression
in vitro, whereas clones from normal donors had low frequencies (1-5 x 10-4). In
addition, the normal CD8+ Tcell clone (CD3''8+) from AT patient 1 also exhibited
a high frequency of spontaneous loss of surface TCR/CD3 in vitro (although the
data is not shown). These results suggest that the high frequency ofin vivo variants
in ATpatientsis not attributable toabnormal differentiationofTcells in thethymus,
but to the intrinsic instability of TCR genes in mature T cells.
Discussion
In this paper, we have demonstrated the presence of variant CD4+ T cells with
alterations ofTCR/CD3 expression in human PB. These variant clones were found
to haveabnormalities intheexpression ofoneofthechains intheTCRheterodimer,
and they expressed the incomplete TCR/CD3 complex in the cytoplasm orthe cell
surfaceatvariouslevels. We assume that thein vivovariant isgenerated not bydefects
in productive rearrangements of TCR genes in the thymus (followed by failures to
eliminatethecells), butby spontaneous somaticmutation, such inactivation, partial
deletion, and point mutation ofproductively rearranged TCR genes in the periph-
eral mature T cells. The first reason for this consideration is the increase ofvariant
frequency with age (Fig. 7), which indicates the accumulation of abnormal clones
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Spontaneous loss of TCR/CD3 expression in vitro in CD4' T cell clones derived
from AT patients. CD4' Tcell clones normally expressing the TCR/CD3 were established from
AT patient no. 1 (A and C), listed in Fig. 7, and a normal donor (B). T cells logarithmically
proliferating in culture were stained with either FL-anti-CD4 (Leu-3a) andPE-anti-CD3 (Leu-
4) (A and B) or FL-WT31 and PE-Leu-4 (C). After staining dead cells (DC) with propidium
iodide, 5 x 105 cells were analyzed, as described for Fig. 1. Contours differ by a factor of 10
in events perchannelwith a minimal dot indicating oneeventperchannel. The cell frequency
in the windows are shown in the figure.
in the PB after thymus involution. Second, a high variant frequency was observed
in AT patients (Fig. 7), who also have a high frequency oferythrocytemutation and
lymphocyte chromosome aberrations. Third, spontaneous inactivation ofTCR/CD3
expression occurred at a similarfrequency in cloned mature T lymphocytesin vitro
(Fig. 8). Fourth, ionizing radiation could induce TCR gene inactivation in vitro
in a dose-dependent fashion in T lymphoma cells (unpublished observation), and
significant elevationofthevariantfrequencywasobserved in radiation-exposeddonors
(Kyoizumi, S., et al., manuscript in preparation).KYOIZUMI ET AL.
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IfTCR gene abnormalities are the results ofsomatic mutation, the variant fre-
quency of2.5 x 10-4, which is equal to 1.3 x 10-9 per single TCR locus (a simple
calculation made by consideringthedimeric structure ofTCR and an allelic exclu-
sion in TCR genes), is -10-100 times higher than that ofother gene loci, such as
T cell hypoxanthine guanine phosphoribosyltransferase (49-51), erythrocyte gly-
cophorin A (32-34), and Tcell HLA class I antigen (52), but it is comparable with
those ofB cell Ig genes (53-57). It has been reported that inactivation of IgH or
L chain genes in myeloma and hybridoma cell lines (53-55) and reversion of the
amber mutation of the IgH gene in the pre-B cell line (56, 57) occurred at a high
rate (10-3 to 10`5 per cell per generation). These Ig mutational events include many
types ofgeneticchanges, suchasdeletions, pointmutations, and frameshifts (58-61).
Such a high rate of alteration of the active Ig genes is believed to be reflected by
the instability ofIg genes in the normal process of B cell differentiation, including
the rearrangements ofV region gene, the class switch ofIgH gene, and the induc-
tion ofpointmutations in theVregion genes forthegeneration ofdiversity(62-64).
The Igrecombination system inB cells may also participateinmediating transloca-
tion of the Burkitt's lymphoma chromosome at breaking points 2p11, 14832, and
22811, where the IgK, IgH, and IgX genes are located (65). Like the Ig genes of B
cells, theTCR genes areprogrammed to dynamically rearrangein thethymus during
T cell ontogenesis, so that the TCR genes ofT cells are presumed to be inherently
unstable and be prone to chromosome aberrations even after rearrangement. A re-
cent report has shown that an immature T cellline can spontaneously undergo sec-
ondary rearrangements in vitro replacing the preexisting productive VaJa rear-
rangements (66), although the frequency of such rearrangements is unknown. It
is presumed that such secondary rearrangements ofTCR genes might be occasion-
ally or frequently nonproductive, and this would be the candidate for one of the
TCR inactivation mechanisms.
Manystudies usingvariant Tcell lineslackingachain ofthe TCR/CD3 complex
haveshown that incompletely assembled receptor complexes do not reachthe plasma
membrane (7-15). The present results also demonstrated that in vivo derived T cell
variantslacking TCRa or-aprotein (type I variants)didnot express the TCR/CD3
complex on the surface. Further, itis noteworthy that three type II variants bearing
a shortened TCR-a and -0 chain, probably a partial deletion, were able to express
alow amount ofthe TCR/CD3 complex on the surface. The shortened TCR chain
was able to form a disulfide-linked heterodimer with the other normal TCR chain,
as shown in Fig. 4, indicating the retention ofthe cystein residue in the C region
proximal to transmembrane domain (7, 19). Since the transmembrane domain of
TCR, especially the region including some basic amino acid residues, appears to
be essential for the association with CD3 molecules (7, 67), the deletion of TCR
should not include this region in membrane domain. In addition, this incomplete
heterodimer was reactive with ctFl orflF1 antibodies but not with WT31 antibody.
All these results suggested that the shortened TCR chains possessed an internal de-
letion in the portion of the C region, which is recognized by WT31 antibody and
probably isdistal to thetransmembrane domain. The small internal deletion in the
C region might directly or indirectly induce conformational changes ofthe CD3-
bindingportion, includingthetransmembrane domain, resultinginadecreasedaffinity1994
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for molecular assembly. Thus, most of the incomplete TCR chains would not form
astable molecularcomplexin the endoplasmic reticulumto be exported to the plasma
membrane, and seem to enter the degradative pathway. Sequence analysis of the
cDNA from the shortened TCR mRNA will localize the deletions and their role
of the deleted portion in molecular assembly and transport.
The variants include the CD4' clone bearing altered TCR-y/& expression. The
TCR-y/& dimer is mainly expressed in CD4-8- non-MHC-restricted cytotoxic T
cells (4-6), and infrequently in intestinal cytotoxic CD8+ T cells (68). Recent re-
ports have suggested the presence of peripheral CD4' T lymphocytes bearing TCR
y/& at alow frequency (25, 69). We have also confirmed these observations and es-
tablished 17 CD4' TCRy/&' clones from PB. All were found to be strongly reac-
tive with both antiTCR&1 and antiTCRy/&1 antibodies and expressed CD3 an-
tigen at a higher level than that of TCR-a/,0-bearing CD4' T cells. SDS-PAGE
analysis of 1251-labeled immunoprecipitates from these clones showed TCRy and
-& chains (37-44 kD) (Kyoizumi, S., M. Akiyama, Y. Hirai, andY. Kusunoki, manu-
script submitted for publication). Since the surface expression of CD3 antigens on
the TCR-S1 + variant established here was much lower than that of normal CD4'
lymphocytes expressing the y/& heterodimer, we presumed that the mutation that
occurred in the TCRy or -& chain also affected the surface expression of the TCR
y/&-CD3 complex, an effect similar to that seen on the TCR-u/0-CD3 complex.
Only a minor population (5-10%) of the CD4' variants detected by flow cytom-
etry could be cloned in vitro by culturingwith PHA and IL-2 . The majority of vari-
ants could not be cloned. This inability suggested that the surface expression of the
TCR/CD3 complex affected the activation pathway initiated by PHA to enter the
growth cycle from the Go state in association with the induction of IL-2-R expres-
sion. The CD2 molecule appears to be a PHA-binding protein (70), and may be
involved in the growth activation pathway. Many studiesusingmutant Tlymphoma
cell lines have provided evidence for functional interaction between the CD2 an-
tigen and the TCR/CD3 complex in stimulation of IL-2 production by anti-CD2
antibody (9, 12-15). Arecent report has also shown the physical association between
these two structures on the cell surface (71). We speculate that without TCR/CD3
expression, theCD2 molecule cannot transmit the growth signal after PHA binding
for the majority of T cells. In contrast, -10% of the sorted variants did respond
to PHA and did grow in culture with IL-2. Possibly, these variants have an alterna-
tive pathway forgrowth stimulation afterCD2-PHAbinding. We presumethat other
hypothetical CD2-associated molecules (71) that can substitute for TCR/CD3 and
function in CD2-mediated growth triggering might be expressed by a minor T cell
population. The variant clones established here might be derived from this minor
population. Similar results were obtained by Moretta et al. (12) using variants de-
rived from the IL-2-producing Jurkat cell line. They showed that -90% of the
TCR/CD3- variant clones (eight of nine clones) did not respond to PHA in spite
oftheirCD2 expression, whileonly one clone could be activatedby PHA to produce
IL-2. The latter appears to correspond to our clonable variants.
Of particular interest is the abnormally high frequency of variant T lymphocytes
in vivo and in vitro in AT patients who show the high incidence of T lymphoma
carrying translocations and inversions in chromosomes 7 and 14 (18, 39, 42, 43).
Analyses of T cell leukemia and peripheral T cells derived from AT patients haveKYOIZUMI ET AL.
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demonstrated thedirect involvement of theTCR-ot and -(3genes in the translocation
ofchromosomes 7 and 14 (72, 73), although causativerelationship between the trans-
locations and the developmental mechanism of T lymphoma is still unknown. Fur-
thermore, many studies have shown abnormalities of T cell function in. most AT
patients (45-48), including decreased responses to mitogens, impaired production
of lymphokines, and defects of the Th cell function in Ig production. It was also
reported that AT patients have abnormal thymus development (44). Since the
TCR/CD3 complex must be directly or indirectly involved in both Tcell functions
anddevelopment, spontaneousinactivation of theTCR gene might significantly con-
tributeto the array of T cell-mediated defects. We presumethat in AT patients there
might be a causal relationship between the high frequencyofthe TCR gene inacti-
vations observed here, the high rate of t(7:14), the high incidence of T lymphoma
development, and the immunodeficiency of T cells. Similarly, in normal individ-
uals, the observed increment of the variant frequency with aging might be related
to theage-dependent increase in the incidenceof chronic lymphocytic leukemia (74),
including T lymphoma, which is frequently associated with t(7:14) translocations
(18), and the age-dependent decrease of T cell functions for immune response (38).
Summary
The TCR/CD3 complexplays acentralrole in antigen recognition and activation
of mature T cells, and, therefore, abnormalities in the expression of the complex
should induce unresponsiveness of T cells to antigen stimulus. Using flow cytom-
etry, we detected and enumerated variant cells with loss or alteration of the surface
TCR/CD3 expression among human mature CD4+ T cells. The presence of variant
CD4+ T cells was demonstrated by isolating and cloning them from peripheral
blood, and their abnormalities can be accounted for by alterations in TCR expres-
sion such as defects of protein expression and partial protein deletion. The variant
frequency in peripheral blood increased with agingin normal donors andwashighly
elevated in patients with ataxia telangiectasia, an autosomal recessiveinheriteddis-
ease with defective DNA repair andvariable Tcell immunodeficiency. These findings
suggest that such alterations in TCR expression are induced by somatic mutagen-
esis ofTCR genesand canbe important factors related to age-dependent and genetic
disease-associated T cell dysfunction.
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